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MicroRNA (miR)-146a-deficient mice develop low-grade, chronic, and systemic inflammation, similar to
inflammaging. Hu et al. (2014) demonstrate that the lack of miR-155 prevents the accumulation of Tfh cells
and inflammaging in miR-146a-deficient mice. They identify Fosl2 as a functionally important target of
miR-155 in Tfh cells.An efficient immune system mounts
potent immune responses to defend
against external and internal threats and
then resolve the response once the threat
is eliminated. Although human beings are
living longer, we realize advanced age
is also accompanied by defects in both
initiation and resolution of immune
responses. In the elderly, declining im-
mune responsiveness (immunosenes-
cence) causes increased susceptibility to
infections and impaired efficacy of vacci-
nation; and paradoxically, unresolved
low-grade inflammation (inflammaging) is
associated with cardiovascular disease,
cancer, and other end-organ diseases.
Compared to younger adults, the immune
system in older adults is characterized
with reduced naive T cells, increased
memory differentiation, and elevated
amounts of proinflammatory cytokines,
such as interleukin-6 (IL-6) and tumor ne-
crosis factor alpha (TNF-a). Such changes
likely result from chronic antigen expo-
sure in the elderly. Consistent with this
observation, HIV-infected individuals,
even under antiretroviral therapy, demon-
strate accelerated ‘‘aging’’ of the immune
system (Deeks, 2011). In this issue of
Immunity, Hu et al. (2014) identify two
microRNAs (miRNAs), miR-155 and miR-
146a, that regulate follicular helper T
(Tfh) cell differentiation and the accumula-
tion during chronic and low-grade inflam-
mation. Not only does the new study
extend our knowledge on the sophisti-
cated regulatory circuit in Tfh cells, but
it also paves the way to understand the
previously unappreciated role for Tfh cells
in inflammaging.
Tfh cells are a subset of CD4+ helper
T cells specialized in regulating antibody
responses. In germinal centers (GCs),
Tfh cells express costimulatory receptorson the surface and secrete helper cyto-
kines to support GC B cells to undergo
multiple rounds of mutation-selection in
B cell receptors. In the current model,
upon optimal cognate interactions with
Tfh cells, high-affinity GC B cells differen-
tiate into memory B cells and plasma cells
(Ma et al., 2012).
The differentiation and function of
Tfh cells are critically regulated by tran-
scription factors, with Bcl6, STAT3,
Ascl2, IRF4, BATF, and c-MAF generating
a major driving force and Blimp-1, STAT5,
Foxo1, and Foxp1 acting to antagonize
(Ma et al., 2012; Yu et al., 2014) (Figure 1).
In addition to such transcriptional
regulation, there is emerging evidence
that miRNA-mediated posttranscriptional
regulation also joins the regulatory
network to determine the Tfh cell fate.
MiRNAs are endogenously produced
small RNAs (21 nucleotides) that target
specific mRNAs through partially comple-
mentary base-pairing to destabilize tar-
get mRNAs and inhibit their translation
(Baumjohann and Ansel, 2013). Blocking
miRNA biogenesis impairs CD4+ T cell
proliferation and survival. Each T helper
(Th) cell subset displays a distinct miRNA
expression profile, and many miRNAs
have been identified with specific func-
tions in individual Th cell subsets (sum-
mary in Baumjohann and Ansel, 2013).
Notably, miRNA expression is especially
important for Tfh cell differentiation.
Without global miRNA expression, Tfh
cell differentiation is severely impaired,
whereas the differentiation of other Th
subsets, particularly Th1, is enhanced.
This defect of Tfh cell differentiation can
be partially explained by the lack of a
miRNA cluster, miR-17-92. MiR-17-92 is
induced early in CD4+ T cell activation,
peaks at the early stage of differentiation,Immunity 41and then decreases to an amount lower
than that in naive CD4+ T cells. The upre-
gulation of miR-17-92 during initial activa-
tion is considered to suppress the expres-
sion of two phosphatases PTEN and
PHLPP2 to remove the inhibition of
ICOS-PI3K-Akt signaling pathway to pro-
mote Tfh cell differentiation. It might also
suppress the expression of the transcrip-
tion factor Rora to prevent alternative dif-
ferentiation into Th17 cells (Baumjohann
and Ansel, 2013) (Figure 1).
In this new study, Hu et al. (2014)
revealed additional miRNAs playing roles
in the regulation of Tfh cells. Previously,
miR-146a-deficient mice were shown
to develop systemic inflammatory and
autoimmune pathology. Although both
myeloid hyperproliferation and dysfunc-
tional regulatory T (Treg) cells contribute
to this phenotype, miR-146a deficiency
in conventional T cells is sufficient to drive
chronic inflammation in an autonomous
manner (Yang et al., 2012). T cell receptor
(TCR) stimulation induces the activation
of NF-kB and subsequently upregulates
the expression of miR-146a. MiR-146a
serves as a negative-feedback regulator.
It represses the NF-kB signaling trans-
ducer TRAF6 and IRAK1 to curb NF-kB
activity (Yang et al., 2012) (Figure 1).
Over time, CD4+ T cells from mice
deficient of miR-146a became biased to
Tfh cell differentiation, with mild changes
in Th1 and Th17 cell differentiation (Hu
et al., 2014). It is not unexpected that
enhanced NF-kB signaling in miR-146a-
deficient mice promotes Tfh cell accumu-
lation. Tfh cell differentiation and mainte-
nance requires lasting TCR signaling and
chronic antigenic stimulation as seen in
viral persistence progressively redirects
CD4+ T cell differentiation away from the
Th1 cell response induced during an, October 16, 2014 ª2014 Elsevier Inc. 509
Figure 1. The Regulatory Roles of Several Key miRNAs during Tfh Cell Differentiation
Tfh cell differentiation is driven by synergetic signals from TCR, costimulation, and cytokines. MiR-146a
and miR-155 join a network of other miRNAs and transcription factors to regulate this process. MiRNAs
and transcription factors can either play positive (green) or negative (red) roles.
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Accumulation of Tfh cells in miR-146a-
deficient mice in advancing age was
associated with spontaneous GC forma-
tion and autoantibody production (Hu
et al., 2014). Active differentiation of Tfh
cells driving autoantibody production is
a feature of autoimmune patients such
as those with systemic lupus erythemato-
sus (SLE) (He et al., 2013). Intriguingly,
SLE patients were reported with miR-
146a underexpression and the asso-
ciation with a high-risk allele carrying
a functional variant in miR-146a pro-
moter impairing its induction (Shen
et al., 2012). Future studies are required
to determine the relationship between
miRNA-146a underexpression and Tfh
cell functionality in human diseases.
As ‘‘a tale of two miRNAs,’’ the authors
identified miR-155 as a negative regu-
lator in miR-146a-deficiency-induced in-
flammaging. Mice deficient with both
miR-155 and miR-146a showed no accu-
mulation of Tfh cells and GCs. Impor-
tantly, inflammatory and autoimmune
pathologies in miR-146a-deficient mice
are completely prevented by the lack of
miR-155. Therefore, loss of miR-155 is
essentially epistatic to a deficiency in510 Immunity 41, October 16, 2014 ª2014 ElmiR-146a for the inflammaging pheno-
type. This notion is also supported by
the clustering analysis of gene expression
in CD4+ T cells from wild-type (WT),
single, or double gene-deficient mice,
which indicated that the gene-expression
profile from double gene-deficient CD4+
T cells was closest clustered with that
from Mir155/ cells (Hu et al., 2014).
A similar observation was reported in
Th1 cell response for antitumor immunity.
Mir146/ mice possessed enhanced
Th1 cell response and better inhibition of
tumor growth, whereas both Mir155/
and Mir155/Mir146/ mice demon-
strated dampened IFN-g production in
CD4+ and CD8+ T cells with worse tumor
growth than WT mice (Huffaker et al.,
2012).
TCR engagement induces mir-155
expression. MiR-155 is required for Th1
cell differentiation and Mir155/ CD4+
T cells preferentially differentiate into the
Th2 cell subset. Several targets for miR-
155 have been studied: c-MAF, SOCS1,
SHIP1, and IFN-gRa. Nevertheless, there
is a certain discrepancy of target valida-
tion. One explanation is that the signifi-
cance of each regulation might be cell-
type and immune-response dependent
(Lind and Ohashi, 2014).sevier Inc.By generating miR-155 conditional
gene deletion mice in T cells (Cd4-cre),
the authors convincingly revealed the
intrinsic requirement of miR-155 in CD4+
T cells for Tfh cell differentiation,
in models of protein antigen immuniza-
tion, infection, and miR-146a-deficiency-
induced inflammaging. The defect of Tfh
cell function due to miR-155 deficiency
in CD4+ T cells led to the reduction of
GC formation and antigen-specific anti-
body production. Hu et al. use a systemic
biology approach to search for miR-155
targets specifically in Tfh cells and identi-
fied two new targets: Fosl2 and Peli1.
Indeed, knockdown of Fosl2 inMir155/
CD4+ T cells markedly rescued the gener-
ation of Tfh cells (Hu et al., 2014). It is
conceived that higher amounts of Fosl2
in Mir155/ CD4+ T cells increase the
competition with BATF to recruit IRF4.
Therefore, Tfh cell differentiation is in-
hibited due to weaker BATF and IRF4
functions (Figure 1).
This study uncovers the new role of
miR-146a and miR-155. They have now
joined with other transcription factors
and miRNAs in a regulatory circuit for
Tfh cell differentiation and function. Data
shown here highlight the importance of
sustained TCR signaling and costimula-
tory signaling to induce the activation of
the PI3K-Akt pathway for Tfh cell differ-
entiation (Figure 1). Future investigation
is required to dissect synergetic and
antagonistic relationships among these
regulatory elements and also to under-
stand the stepwise specificity of the
regulation at different stages including
initiation, differentiation, and mainte-
nance of Tfh cells.
The study sheds light on the possible
role of Tfh cells, GC response, and auto-
antibodies in the process of inflammag-
ing. It will be interesting to examine
the development of inflammatory pathol-
ogy in miR146a-deficient mice or other
models by preventing Tfh cell function
via miR-155 deficiency or other means.
If the pathogenic role of Tfh cells and
GC responses is confirmed, approaches
can be taken to target this pathway to
ameliorate inflammation for a healthier
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Intestinal pathobionts that escape into the periphery can cause serious morbidity and death. In this issue of
Immunity, Hasegawa et al. (2014) show that the host’s protectivemeasures against such events include inter-
leukin-22-driven systemic elimination of pathobionts via complement regulation.An extraordinary number and variety of
microbes populate our gastrointestinal
system. During evolution, the host and
the gut microbiota establish a complex
relationship that is now acknowledged
as being well beyond mere coexistence
such that it has an explicit mutualistic
nature whereby the intestinal flora is often
considered a microbial organ placed
within the gut. The gut microbiota regu-
lates host energy balance and mediates
normal production of several vitamins
and hormones as well as water adsorp-
tion. Moreover, intestinal bacteria are
critically required for the development
of gut-associated lymphoid organs and
protect the host from colonization with
invading harmful microbial species and
pathogens throughout life.
However, maintaining the integrity of
the intestinal barrier and sustaining a
homeostatic balance among the dynamic
microbiota are key to health because
the normal gut flora contains several
potentially virulent species, called patho-
bionts, that can cause disease when they
escape into the host’s periphery (Hase-
gawa et al., 2012). For example, the com-
mon treatment of hospitalized patients
with broad-spectrum antibiotics resultsin alterations of the normal intestinal
microbiota and fosters overgrowth of
pathogenic Gram-positive spore-forming
Clostridium difficile, which is normally
prevented by commensals. C. difficile-
derived toxins then damage the intestinal
epithelium, which leads to translocation
of intestinal bacteria into the extrain-
testinal space and causes infectious
diarrhea and pseudomembranous colitis.
Thus, C. difficile infection is a disease
with a largely iatrogenic cause and with
worrying rising incidence and increasing
severity of pathogenesis: elimination of
C. difficile with vancomycin and/or
metronidazole is ineffective in about
4%–7% of patients, and C. difficile
infection can be fatal specifically in the
frail, elderly, or immunocompromised.
Importantly, recent work in the field
strongly indicates that commensals and/
or pathobionts that have breached the
compromised epithelial barrier during
C. difficile infection and accumulate
in extraintestinal organs and tissues
contribute to disease pathogenesis and
mortality (Hasegawa et al., 2012). How-
ever, the underlying mechanisms sup-
porting peripheral pathobiont dissemi-
nation and the measures taken by thehost’s immune system are unanswered
questions.
The current study by Hasegawa et al.
(2014) delivers some important mecha-
nistic insights into these complex events
in C. difficile infection. The authors have
examined the role of interleukin-22 (IL-
22) in C. difficile infection in protec-
tion against secondary pathobiont sepsis
and survival. Using an established animal
model, the study first observed strikingly
lower survival rates in Il22/ mice than
in wild-type control mice after C. difficile
infection. This was shown to be associ-
ated with the translocation of ordinarily
‘‘commensal’’ bacteria (or pathobionts)
of the predominant g-enterobacterial
type to extraintestinal sites, such as the
liver and lung, only in IL-22-deficient
mice. These mice, however, could be
rescued either by elimination of patho-
bionts by targeted antibiotics or through
administration of recombinant IL-22.
Although the central role of IL-22 in the
prevention of pathobiont translocation
has previously been acknowledged (Aujla
et al., 2008; Basu et al., 2012; Sonnenberg
et al., 2012), a novel mechanistic link be-
tween IL-22 and enhanced pathobiont
killing was then elegantly identified by, October 16, 2014 ª2014 Elsevier Inc. 511
